Stavros G. Vizirgianakis - 15 Aug 2026 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Reporting relationship: Director
Issuer ticker: XTNT
Reported as of: 15 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 18:09:24 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

Stavros G. Vizirgianakis filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 18 Aug 2026.

Key facts

This page summarizes Stavros G. Vizirgianakis's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 18:09.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559834 Primary reporting owner

Vizirgianakis Stavros G.

Relationship: Director
Address: C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE, BELGRADE
Signature: /s/ Amy Culbert, attorney-in-fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock

Award

Transaction value
Shares: +323,275
Change %: +4.3%
Price: $0.000000^*
Shares after: 7,838,845
Date: 15 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes 1,843,491 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.